Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients ...
- Presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 am PT (11:15 am ET) - "2025 marked a year of disciplined execution and substantial advances in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results